Evoke Pharma Inc (EVOK) — Cash Flow-to-Debt Ratio
Evoke Pharma Inc (EVOK) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of $-521.96K could theoretically repay 0% of its total liabilities ($12.29 Million) in one year. See Evoke Pharma Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Evoke Pharma Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Evoke Pharma Inc across 14 annual periods. Also explore EVOK year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Evoke Pharma Inc (2011–2024)
Year-by-year debt coverage analysis for Evoke Pharma Inc. For market capitalisation and broader financial context, see how much is Evoke Pharma Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | $-5.46 Million | $10.48 Million | ▼ -0.8% |
| 2023 | -0.52x | $-4.98 Million | $9.65 Million | ▲ +39.2% |
| 2022 | -0.85x | $-6.60 Million | $7.77 Million | ▲ +51.8% |
| 2021 | -1.76x | $-12.35 Million | $7.02 Million | ▼ -235.8% |
| 2020 | -0.52x | $-6.63 Million | $12.65 Million | ▲ +81.7% |
| 2019 | -2.86x | $-5.76 Million | $2.02 Million | ▲ +33.0% |
| 2018 | -4.27x | $-6.98 Million | $1.63 Million | ▼ -182.9% |
| 2017 | -1.51x | $-8.72 Million | $5.78 Million | ▲ +4.6% |
| 2016 | -1.58x | $-8.71 Million | $5.51 Million | ▲ +8.6% |
| 2015 | -1.73x | $-10.50 Million | $6.07 Million | ▲ +8.1% |
| 2014 | -1.88x | $-11.50 Million | $6.11 Million | ▼ -135.4% |
| 2013 | -0.80x | $-3.04 Million | $3.80 Million | ▼ -803.4% |
| 2012 | -0.09x | $-1.75 Million | $19.78 Million | ▲ +43.2% |
| 2011 | -0.16x | $-2.89 Million | $18.56 Million | — |